Sanara MedTech (SMTI) to Release Earnings on Monday

Sanara MedTech (NASDAQ:SMTI) will likely be issuing its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $22.75 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Sanara MedTech Stock Down 1.0 %

Sanara MedTech stock opened at $33.60 on Friday. The stock has a 50-day simple moving average of $34.36 and a 200-day simple moving average of $33.84. The company has a market capitalization of $293.70 million, a P/E ratio of -33.94 and a beta of 1.37. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.02 and a current ratio of 2.23. Sanara MedTech has a fifty-two week low of $26.00 and a fifty-two week high of $39.08.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $44.00 price target on shares of Sanara MedTech in a research report on Wednesday, January 22nd. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Sanara MedTech in a research report on Thursday, January 23rd.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.